Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E. Montes-Servin

Clinical Evaluation of the Utility of a Liquid Biopsy (Circulating Tumoral Cells and ctDNA) to Determine the Mutational Profile (EGFR, KRAS, ALK, ROS1 and BRAF) in Advanced NSCLC Patients

Annals of Oncology

English

Related publications

P1.01-67 Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients

Journal of Thoracic Oncology

English

OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC

Journal of Thoracic Oncology

English

P1.09-12 Simultaneous Platform of Genotyping EGFR, ALK, and ROS1 in Patients With NSCLC Highlights Correlation of ROS1 and PD-L1 Expression

Journal of Thoracic Oncology

English

P2.13-14 the Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy

Journal of Thoracic Oncology

English

MA16.09 Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

PCR-based Detection of EGFR, ALK, KRAS and BRAF Mutations in Russian Patients With Lung Adenocarcinoma: A Single-Center Experience

Neoplasma

Cancer Research

2018

English

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology

English

Costs of ALK , ROS1 , EGFR , and KRAS Testing in Non-Small Cell Lung Cancer: About Different Strategies in France

English

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK Among Treatment-Naïve Patients With Advanced Lung Adenocarcinoma

PLoS ONE

Multidisciplinary

2016

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E. Montes-Servin

Clinical Evaluation of the Utility of a Liquid Biopsy (Circulating Tumoral Cells and ctDNA) to Determine the Mutational Profile (EGFR, KRAS, ALK, ROS1 and BRAF) in Advanced NSCLC Patients

Related publications

P1.01-67 Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients

OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC

P1.09-12 Simultaneous Platform of Genotyping EGFR, ALK, and ROS1 in Patients With NSCLC Highlights Correlation of ROS1 and PD-L1 Expression

P2.13-14 the Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy

MA16.09 Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer

PCR-based Detection of EGFR, ALK, KRAS and BRAF Mutations in Russian Patients With Lung Adenocarcinoma: A Single-Center Experience

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

Costs of ALK , ROS1 , EGFR , and KRAS Testing in Non-Small Cell Lung Cancer: About Different Strategies in France

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK Among Treatment-Naïve Patients With Advanced Lung Adenocarcinoma